Status:
COMPLETED
Endometriosis Patients Undergoing Quinagolide Treatment
Lead Sponsor:
Instituto Valenciano de Infertilidad, IVI VALENCIA
Conditions:
Hyperprolactinemia
Endometriosis
Eligibility:
FEMALE
18-37 years
Phase:
PHASE4
Brief Summary
Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Hyperprolactinemia
- Unexplained infertility
- Endometriosis
Exclusion
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00625950
Start Date
February 1 2008
End Date
May 1 2008
Last Update
January 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Valenciano de Infertilidad
Valencia, Valencia, Spain, 46015